NCT04401761

A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs

Xarelto + Acetylsalicylic Acid: Treatment Patterns and Outcomes Across the Disease Continuum in Patients With CAD and/or PAD

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,189 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The study will focus on effectiveness and safety of rivaroxaban (Xarelto) when given together with acetylsalicylic acid (combination therapy) to patients suffering from coronary artery disease (a condition that affects the blood vessels supplying the heart) and / or peripheral artery disease (a condition that affects the blood vessels of the lower limbs) in the routine clinical practice. The study will help to collect data for prevention cardiovascular death, myocardial infarction (MI), stroke and major adverse limb events in adult patients. The study will focus on information on when and why physicians are starting to treat patients with combination therapy, treatment duration, reasons to discontinue treatment and previous therapies. The study will also investigate treatment outcomes for patients being treated with a combination therapy by their physicians.

Conditions

• Coronary Artery Disease
• Peripheral Artery Disease

Interventions

Type	Name	Description
DRUG	Rivaroxaban (BAY59-7939, Xarelto)	2.5 mg twice daily
DRUG	Acetylsalicylic acid	75 - 100 mg once daily at the discretion of the investigator

Timeline

• Start date: 2020-05-28
• Primary completion: 2023-06-30
• Completion: 2023-09-29
• First posted: 2020-05-26
• Last updated: 2023-10-25

Locations

10 sites across 10 countries: Belgium, China, Colombia, Italy, Russia, Slovenia, South Korea, Spain, Switzerland, Taiwan